Intelligence · Clinical pipeline
Oncology R&D Pipeline
Anticancer agents, immuno-oncology biologics, and oncology pipeline programs from ClinicalTrials.gov — Phase 1 through approval.
Quick answer
Oncology: NovaPharmaNews indexes 5,539 oncology clinical pipeline programs from ClinicalTrials.gov with phase, modality, NCT identifiers, and sponsor company links. Anticancer agents, immuno-oncology biologics, and oncology pipeline programs from ClinicalTrials.gov — Phase 1 through approval.
Top sponsors
- First People's Hospital 474 programs
- Chinese Academy of 400 programs
- United Therapeutics Europe 219 programs
- George Institute for 172 programs
- Takeda 163 programs
- HOFFMANN-LA ROCHE 144 programs
- AstraZeneca 143 programs
- MSD Merck Sharp 131 programs
- Regeneron UK 128 programs
- Anaxis Pharma 125 programs
- Telethon Foundation 113 programs
- Novartis India 110 programs
Pipeline programs
-
Alisertib (MLN8237)
Takeda
Diffuse Large B-Cell Lymphoma
1 trial -
Alitretinoin
LIGAND PHARMACEUTICALS INC
Sarcoma, Kaposi
2 trials -
Alkotinib Capsules
Suzhou Zelgen Biopharmaceuticals Co.,Ltd
ALK-positive Non-small Cell Lung Cancer
1 trial -
Allogenic expanded Natural Killer Cells (AlloNK1)
Hospital Authority, Hong Kong
Nasopharyngeal Carcinoma (NPC)
1 trial -
Almonertinib
Xiyuan Hospital of China Academy of Chinese Medical Sciences
Non-small Cell Lung Cancer
1 trial -
Almonertinib
Xiyuan Hospital of China Academy of Chinese Medical Sciences
Lung Cancer Non-small Cell Stage IV
1 trial -
Almonertinib
The First People's Hospital of Lianyungang
EGFR Positive Non-small Cell Lung Cancer
1 trial -
Almonertinib
The First People's Hospital of Lianyungang
Non Small Cell Lung Cancer
1 trial -
Almonertinib 110 MG
Chinese University of Hong Kong
Rare Tumor
1 trial -
AloCelyvir
The George Institute
mEtastatic Uveal Melanoma
1 trial -
Alpelisib
United Therapeutics Europe Ltd
Breast Cancer
1 trial -
Amcenestrant
Sanofi Pasteur
Breast Cancer Metastatic
1 trial -
Ametinib combined with bevacizumab
The First People's Hospital of Lianyungang
Non-small Cell Lung Cancer
1 trial -
Anlotinib
The First People's Hospital of Lianyungang
Non-Small-Cell Lung Cancer
1 trial -
Anlotinib and Sintilimab injection
The First People's Hospital of Lianyungang
Advanced Hepatocellular Carcinoma
1 trial -
Anlotinib combined Docetaxel
Xiyuan Hospital of China Academy of Chinese Medical Sciences
Non-small Cell Lung Cancer
1 trial -
Anlotinib plus Pemetrexed
Henan Provincial People's Hospital
Non-squamous Cell Non-Small Cell Lung Cancer
1 trial -
Anlotinib+ Liposomal Doxorubicin
The First People's Hospital of Lianyungang
Sarcoma
1 trial -
Anrotinib plus Tirelizumab
Xiyuan Hospital of China Academy of Chinese Medical Sciences
Nasopharyngeal Carcinoma
1 trial -
Anti-BCMA-CAR-transduced T cells
Xiyuan Hospital of China Academy of Chinese Medical Sciences
Leukemia
1 trial -
Anti-CD19 CAR-T
The First People's Hospital of Lianyungang
Acute Lymphoblastic Leukemia ,Lymphomas
1 trial -
Anti-CD19 CAR-T cells and Anti-CD20 CAR-T cells
Xiyuan Hospital of China Academy of Chinese Medical Sciences
Lymphoma, Large B-Cell, Diffuse
1 trial -
Anti-CD20-CAR-transduced T cells
Xiyuan Hospital of China Academy of Chinese Medical Sciences
Leukemia
1 trial -
Anti-CD30-CAR-transduced T cells
Xiyuan Hospital of China Academy of Chinese Medical Sciences
Leukemia
1 trial -
Anti-CD40 Agonist Monoclonal Antibody CDX-1140
United Therapeutics Europe Ltd
Ovarian Clear Cell Adenocarcinoma
1 trial -
Anti-HER2 CAR-T
Xiyuan Hospital of China Academy of Chinese Medical Sciences
Breast Cancer
1 trial -
Anti-PD-1 antibody
Xiyuan Hospital of China Academy of Chinese Medical Sciences
Gastric or Gastroesophageal Junction Adenocarcinoma
1 trial -
Anvumetostat
Amgen
Advanced MTAP-null Solid Tumors
1 trial -
Apalutamide
Janssen Cilag International NV
Salivary Gland Neoplasms
1 trial -
Apatinib
The First People's Hospital of Lianyungang
Lung Cancer
1 trial -
Apatinib
The First People's Hospital of Lianyungang
Advanced Esophageal Squamous Carcinoma
1 trial -
Apatinib
The First People's Hospital of Lianyungang
Breast Cancer
1 trial -
Apatinib
The First People's Hospital of Lianyungang
Intrahepatic Cholangiocarcinoma
1 trial -
Apatinib
Xiyuan Hospital of China Academy of Chinese Medical Sciences
Metastatic Gastric Adenocarcinoma
1 trial -
Apatinib
The First People's Hospital of Lianyungang
Advanced Solid Tumors
1 trial -
Apatinib
Xiyuan Hospital of China Academy of Chinese Medical Sciences
Breast Cancer Metastatic
1 trial -
Apatinib
Chinese University of Hong Kong
Head and Neck Neoplasms
1 trial -
Apatinib
The First People's Hospital of Lianyungang
Systematic Review of the pCR Rate of Apatinib Combined With Albumin Paclitaxel and Carboplatin Regimen for Neoadjuvant Therapy of Triple-negative Breast Cancer
1 trial -
Apatinib
Xiyuan Hospital of China Academy of Chinese Medical Sciences
Lung Cancer
1 trial -
Apatinib
Hospital Authority, Hong Kong
Soft Tissue Sarcoma, Adult, Stage II
1 trial -
Apatinib
The First People's Hospital of Lianyungang
Non Small Cell Lung Cancer
1 trial -
Apatinib Combined With SHR-1210 Injection
The First People's Hospital of Lianyungang
Hepatocellular Carcinoma
1 trial -
Apatinib Mesylate +SHR-1210
Chinese University of Hong Kong
Hepatocellular Carcinoma
1 trial -
Apatinib mesylate tablet
Xiyuan Hospital of China Academy of Chinese Medical Sciences
Nasopharyngeal Carcinoma
1 trial -
Apatinib mesylate tablets
The First People's Hospital of Lianyungang
Gastric Cancer
1 trial -
Apatinib+ SHR-1210（Camrelizumab）
The First People's Hospital of Lianyungang
Esophageal Cancer
1 trial -
Apheresis and Bridging Therapy
The First People's Hospital of Lianyungang
Large B-cell Lymphoma
1 trial -
Ara-C Group
The First People's Hospital of Lianyungang
Acute Myeloid Leukemia
1 trial
Frequently asked questions
How many oncology pipeline programs are tracked?
5,539 programs match this therapeutic area based on indication text, program name, and registry metadata.
Where does pipeline data come from?
ClinicalTrials.gov records linked to NovaPharmaNews company profiles. Verify on ClinicalTrials.gov before investment decisions.